Clinical Trial

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Name: KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — clinical trial record (NCT07260812)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-21.

Trial Details

NCT Number	NCT07260812
Lead Sponsor	TCRx Therapeutics Co.Ltd Collaborators: Tongji Hospital
Conditions	Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment	18 participants
Start Date	2025-09-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-13